Q-omics provides the consensus-scored ZBTB48 profile across patient tissues and cancer cell-line models. ZBTB48 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZBTB48 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ZBTB48 RNA expression shows 19,358 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where ZBTB48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB48 survival associations across molecular data types. ZBTB48 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB48 RNA expression–survival associations across cancer types. High ZBTB48 expression shows unfavorable associations in ACC, COAD and LGG, but favorable associations in PAAD, CHOL and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZBTB48 RNA expression.
This table summarizes ZBTB48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB48 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, COAD and LIHC. The KICH box plot shows higher ZBTB48 RNA expression in normal versus tumor tissue (log2 FC = −1.543, t-test p < 0.001).
This table shows molecular features associated with ZBTB48 in patient tissues and cancer cell lines. In patient samples, ZBTB48 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
